← Leaderboards
John M Hilfinger
Tsrl, Inc.
$14,334,475
Attributed
$14,334,475
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2005–13$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$14,334,475 · 13
By mechanism
R44$5,585,246 · 2
U01$5,315,073 · 1
R43$3,434,156 · 10
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Antiviral Agents”
- Constance Ann Benson · University Of California, San Diego$209,152,068
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
- Judith S. Currier · University Of California Los Angeles$102,391,456
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Sharon A Nachman · Johns Hopkins University$77,262,665
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403
Research focus
Antiviral AgentsProdrugsIntestinesBiological AvailabilityPharmaceutical PreparationsDesignOralParentsVirusUniversitiesUptakeCidofovirAnalogMichiganBaseCellsCollaborationsEvaluationHydrolysisMetabolismLeadCytotoxicitySeriesHuman Cell Line
Grant awards (23)
Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability$1,000,000
R44 · FY2013 · AI · contact PI
Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$300,000
R43 · FY2013 · AI · contact PI
Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability$904,078
R44 · FY2012 · AI · contact PI
Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability$681,168
R44 · FY2011 · AI · contact PI
Novel prodrugs for treatment of human CMV infection$294,693
R43 · FY2011 · AI · contact PI
Novel prodrugs for treatment of human CMV infection$296,764
R43 · FY2010 · AI · contact PI
Oral Antiviral Prodrugs for Biodefense Initiative$1,114,210
U01 · FY2009 · AI · contact PI
Improving Absorption and Targeting of Antiviral Drugs$1,000,000
R44 · FY2009 · AI · contact PI
Development of orally delivered, non-absorbable AT1 receptor antagonists for infl$268,620
R43 · FY2009 · DK · contact PI
Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability$185,621
R43 · FY2009 · AI · contact PI
Oral Antiviral Prodrugs for Biodefense Initiative$1,086,216
U01 · FY2008 · AI · contact PI
Improving Absorption and Targeting of Antiviral Drugs$1,000,000
R44 · FY2008 · AI · contact PI
Oral Antiviral Prodrugs for Biodefense Initiative$1,079,540
U01 · FY2007 · AI · contact PI
Improving Absorption and Targeting of Antiviral Drugs$1,000,000
R44 · FY2007 · AI · contact PI
Vidarabine Prodrugs as Anti-Pox Virus Agents$297,813
R43 · FY2007 · AI · contact PI
Oral Antiviral Prodrugs for Biodefense Initiative$973,994
U01 · FY2006 · AI · contact PI
Enhancing Thrombostatin's Oral Delivery$274,452
R43 · FY2006 · HL · contact PI
Oral Antiviral Prodrugs for Biodefense Initiative$1,061,113
U01 · FY2005 · AI
Improving Absorption and Targeting of Antiviral Drugs$464,811
R43 · FY2004 · AI
Improving Absorption and Targeting of Antiviral Drugs$462,143
R43 · FY2003 · AI
Oral Delivery of Thrombostatin$205,333
R43 · FY2003 · HL
Development of an Oral Anthrax Vaccine$203,609
R43 · FY2002 · AI
MODULATION OF TOLERANCE BY ORAL COMPOSITE NANOPARTICLES$180,297
R43 · FY2000 · AR